NovAliX and Max Planck join forces to advance Cryo-EM driven drug discovery

Collaboration will make vital process of translating scientific research and academic insights into real therapies more efficient and more effective

07-Mar-2024 - NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, announces its long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen. Through this collaboration, NovAliX and the MPI aim to make the vital process ...

Artificial intelligence to reduce costs and improve efficiency in drug discovery

Chemical.AI and NovAliX reached a milestone in collaboration

24-Jan-2023 - Chemcial.AI announces the collaboration with NovAliX -a world-leading Drug Discovery CRO company- has reached a milestone. On January 25, 2021, Chemical.AI announced a strategic cooperation with NovAliX in the field of AI-assisted drug discovery. Over the past two years, ChemAIRS, developed by ...

NovAliX enters into cooperation agreement with Max-Planck spin-off

28-Mar-2018 - NovAliX, a drug discovery-focused Contract Research Organization (CRO) announces that it has signed a cooperation agreement with German-based ProteoPlex GmbH, a spin-off company of the Max-Planck-Institute for Biophysical Chemistry (MPIBPC). Under the terms of the agreement, NovAliX will ...

NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin

17-Jan-2013 - NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan. Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. Under the terms of the agreement ...

NovAliX Names Dr Luc Van Hijfte as CSO Drug Discovery

23-Oct-2012 - NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery. He joined from Janssen, a J&J company, where he served as Head of ...

NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma

16-Jan-2012 - NovAliX SAS announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX ...

NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)

14-Sep-2011 - NovAliX announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the ...

NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program

31-Aug-2011 - NovAliX announces that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos.Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by ...

NovAliX Acquires a Majority Interest in Graffinity

18-Nov-2010 - NovAliX SAS announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH. Financial details of the transaction were not disclosed. NovAliX’ President, Stephan Jenn stated: "The acquisition of Graffinity will be a significant step ...